News

A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.

Despite the availability of anti-VEGF therapies, there is still a notable disease burden in older adults with vision-threatening retinal diseases.

This study’s investigators point to the necessity of adapting an antibiotic stewardship program for acne treatment, with evaluation being done in dermatology practices to assess performance.

Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.

Sibling control analyses showed acetaminophen use during pregnancy was not associated with an offspring’s risk of autism, ADHD, or intellectual disability.

Madrigal Pharmaceuticals announced resmetirom is available in the US beginning on April 9, 2024, ushering in a new era of NASH management.

In the latest Lungcast, Drs. McCurry and Valapour answered several questions on the candidacy of post-infectious COVID-19 patients for lung transplantation and on long COVID.

A study using machine learning models found “I” usage on Facebook posts does not predict depression severity in Black individuals.

An analysis of NHANES data found no significant association between HCV infection and risk of prostate cancer, contrary to findings from previous research.

Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of ninerafaxstat.

Adults with strabismus in a diverse nationwide cohort were approximately 2 to 3 times more likely to experience mental health conditions.

These nationwide data contribute to the overall body of research on extraintestinal inflammatory conditions among MC patients, highlighting the value of studying the mechanisms involved.

Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.

EMERGENT-3 trial showed xanomeline-trospium was effective in improving schizophrenia symptoms at 52 weeks, for participants who took either placebo or KarXT in acute trials.

Findings highlight the safety and efficacy of switching from originator to biosimilar adalimumab, which also showed favorable results in adalimumab-naïve patients with IBD.

In these data, investigators had investigated the international differences in topical AK medication implementation, including links to countries’ different economic statuses.

The study highlights how the experience of loneliness for care partners of people with dementia changes relationship roles throughout the dementia trajectory.

Veraprapas Kittipibul, MD, discusses an analysis of the TRANSFORM-HF trial at ACC.24.

Talal highlights the use of facilitated telemedicine for increasing access to HCV treatment and other areas it might expand access for underserved patient populations.

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

REDUCE-AMI concluded beta-blockers show no significant benefit following myocardial infarction among patients with normal left ventricular ejection fraction

Alberto Foà, MD, PhD, discusses a PARAGON-HF analysis from ACC.24 examining treatment-related hypotension in people with HFmrEF/HFpEF.

Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.

Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.

The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.

New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.

In this ACC.24 episode of Don't Miss a Beat, hosts are joined by Javed Butler, MD, for a breakdown of the EMPACT-MI trial.

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.